Concordantly, HIF2α-activating mutations in humans have been associated with either polycythemia, a condition of elevated hematocrit, or neuroendocrine tumours, including paraganglioma, pheochromocytoma, and somatostatinoma41,50. Here, EPAS1 is linked to polycythemia.